KPV is a three-amino-acid peptide (lysine-proline-valine), the tail end of alpha-MSH. Its reported benefits, mainly less gut inflammation, come from mouse colitis models and cell studies published since 2003. There are no human trials, so side effects in people are unknown, and ClinicalTrials.gov lists no registered study. An FDA advisory committee recommended KPV for pharmacy compounding in July 2026, but as of 9 October 2026 FDA has published no rule, so it is still not lawful to compound. Across 33 lab-tested research vials from February to June 2026, median purity was 99.93% and none failed identity, but 4 held less KPV than the label said.
Research notes
KPV is three amino acids long: lysine, proline and valine. It is the tail end of alpha-melanocyte-stimulating hormone, and the part of that hormone that calms inflammation. The benefits people search for come from mouse colitis models and cell cultures. No human trial exists: a ClinicalTrials.gov search for "KPV" or "Lys-Pro-Val" returned zero registered studies on 9 October 2026.
This page rests on two tables. The benefits table grades each claimed benefit by its best evidence. The testing table summarises 35 third-party certificates covering 33 distinct KPV analyses from February to June 2026: median purity 99.93%, no identity failures, and four vials under label.
What is KPV peptide?
Alpha-MSH is a thirteen-residue hormone best known for driving pigmentation, and it is also anti-inflammatory. Researchers found in the late 1980s and 1990s that the anti-inflammatory activity survives when the hormone is cut down to residues 11 to 13, Lys-Pro-Val. That fragment is KPV.
In gut tissue, KPV mostly skips the melanocortin receptors that full α-MSH uses. Dalmasso and colleagues showed in 2008 that PepT1, a transporter the small intestine uses to absorb protein fragments, carries KPV into gut and immune cells (Gastroenterology, 2008). Healthy colon expresses little PepT1 and inflamed colon much more, so the transporter is most active where the inflammation is.
Inside the cell, KPV suppresses NF-κB and MAP-kinase signalling and cuts cytokine output. Dalmasso's group saw the effect at 10 nM, and blocking PepT1 abolished it. A 2003 mouse study found KPV kept working in animals with a non-functional MC1 receptor, which points away from the classic melanocortin route (Getting, JPET 2003). In human airway cells, KPV blocked the NF-κB subunit p65 from entering the nucleus (Land, 2012).
Melanotan II comes from the same hormone but was built to hit melanocortin receptors hard, for the pigmentation effect KPV leaves behind.
What are the benefits of KPV peptide?
Every benefit below comes from animals or cells. Each row gives the best evidence behind the claim and the study, so you can check it.
| Claimed benefit | Best evidence | What the study found |
|---|---|---|
| Less gut inflammation (colitis) | Animal, replicated | Oral KPV cut colitis in two mouse models, with neutrophil activity (MPO) down about 50% in DSS colitis (Dalmasso 2008). Injected KPV sped recovery in DSS and transfer colitis (Kannengiesser 2008). |
| Gut-targeted delivery | Animal | Nanoparticles in a chitosan/alginate gel delivered KPV to the colon and matched free KPV at a 12,000-fold lower concentration (Laroui 2010); hyaluronic-acid nanoparticles also reduced colitis (Xiao 2017). |
| Lower colitis-linked tumours | Animal, single study | KPV prevented colitis-associated tumours in normal mice but not in mice lacking PepT1 (Viennois 2016). |
| Less systemic inflammation | Animal | KPV reduced white-cell influx in mouse peritonitis (Getting 2003). |
| Airway inflammation | In vitro (human cells) | KPV lowered IL-8 and eotaxin release from human bronchial cells (Land 2012). |
| Skin inflammation | In vitro (human cells) | KPV at 50 μg/mL protected keratinocytes exposed to fine dust (Sung 2025). |
| Wound healing | Review / in vitro | Reviewers list KPV as a candidate, not a proven agent (Böhm 2019). |
| Any human outcome | None | No published or registered human trial for any indication. |
The last row matters most. KPV has a clear mechanism and consistent animal data, but no controlled human trial, so nobody knows whether the mouse gut results carry over to people or at what dose.
KPV for men: no study looked at any male-specific outcome, and Dalmasso used female mice. KPV and cancer: the only relevant study found KPV lowered colitis-driven tumours in mice. Nobody has shown KPV treats or prevents cancer in people.
How pure is the KPV being sold?
Purity is high and identity is clean; label content varies. For single-compound KPV we hold 34 Kovera Labs certificates (retrieved from Kovera's verifier on 1 August 2026) and one Janoshik public report (public listing mirrored to 30 June 2026). Two Kovera certificates reissue one analysis under other brand names: lot GY78N appears with identical results for three sellers. That leaves 33 distinct vials from roughly 30 brands, analysed between 16 February and 10 June 2026.
| Measure | Result |
|---|---|
| Certificates (Kovera + Janoshik) | 35 (34 + 1) |
| Distinct lab analyses | 33 |
| Median HPLC purity | 99.93% |
| Purity range | 99.11% to 99.99% |
| Below 99% purity | 0 |
| Identity failures | 0 |
| Median content vs label (32 Kovera analyses with a label) | 114% |
| Content range | 92.2% to 128.8% of label |
| Under labelled content | 4 of 32 |
| More than 20% over label | 3 of 32 |
Every vial cleared 99% purity, which puts KPV among the cleanest compounds we track. Four 10 mg vials came in short on content: 9.22 mg (92.2%, sold as "Upgrade"), 9.48 mg (94.8%, Phase One Labz), 9.61 mg (96.1%, a client listed only by email) and 9.72 mg (Ascension Peptides, 97.2%). At the other end, three vials held more than 12 mg, 25% to 29% over label, and Kovera flagged those as dose mismatches. Overfill is the norm: 28 of the 32 Kovera analyses came in over label.
The one Janoshik report, for Longevity Pro's, measured 12.76 mg at 99.12% purity, analysed 14 May 2026. Janoshik's public listing also shows KLOW blends containing KPV, which we cover separately.
Two caveats apply to every certificate. It covers the batch that was tested, not the vial in your hand, so the lot number on the vial has to match the lot on the certificate. And Kovera revises certificates in place under the same reference number (our record of revisions), so note the date you retrieved it. To check a Kovera code yourself, follow the six verification steps; our COA verifier handles Janoshik reports.
What KPV doses did studies use?
These are research protocols as the papers report them. They are mouse and cell figures, and none is a human dose.
| Study | Model | Route | What was given |
|---|---|---|---|
| Dalmasso 2008 | Mouse DSS and TNBS colitis | Oral, drinking water | 100 μM KPV, chosen from earlier α-MSH colitis work |
| Dalmasso 2008 | Human gut and T cells | Cell culture | 10 nM |
| Kannengiesser 2008 | Mouse DSS colitis | Intraperitoneal | 10 μg per day, the best dose in their dose-finding |
| Kannengiesser 2008 | Mouse transfer colitis | Intravenous | 0.1 μg, three times a week |
| Laroui 2010 | Mouse DSS colitis | Oral nanoparticles in gel | KPV at 12,000-fold lower concentration than free KPV, similar effect |
| Sung 2025 | Human keratinocytes | Cell culture | 50 μg/mL |
The "KPV dosage charts" on vendor and forum pages do not come from any of these papers. They convert mouse figures or use round numbers with no source. For scale, a 10 mg research vial holds a thousand times the 10 μg daily amount Kannengiesser gave a mouse.
Oral KPV vs injection
Both routes worked in mice. Oral KPV in drinking water worked because PepT1 in the inflamed gut pulls it into cells, which is why most delivery research since 2010 has focused on oral nanoparticles and hydrogels. Injected KPV worked in Kannengiesser's mice. No study compares the routes in people, and oral capsules sold today have no published absorption data.
What are the side effects of KPV?
Side effects in humans are unknown, because no controlled human study exists. The animal and cell work shows this much:
- Animal tolerance. Dalmasso's mice given KPV alone showed no change in colon inflammation markers. Kannengiesser reported no body-weight change in mice given KPV alone. Xiao's nanoparticles were non-toxic to gut cells.
- Receptor activity. KPV largely avoids melanocortin receptors in gut cells, so the tanning and libido effects of melanotan-type peptides are not expected. One 2004 study did see KPV signal through MC1R in engineered cells (Elliott 2004), so that route is not ruled out.
- What is not known. Long-term exposure, immune reactions to repeated injection, interactions with other drugs, and effects in pregnancy have never been studied.
For a research vial, the concrete risks come from the product: wrong content, bacterial contamination, endotoxin or an unexpected solvent. One September 2026 Reddit thread reported KPV shipped with a reconstitution solution containing acetic acid (r/PeptidePathways). A certificate only speaks to the batch the lab tested.
Is KPV legal after the July 2026 FDA vote?
Update, 29 October 2026: HHS filed an interim enforcement-discretion policy (Federal Register, 30 October). It says HHS does not intend to act against 503A pharmacies and physicians compounding KPV acetate for topical or oral use. The conditions include a patient-specific prescription, a single ingredient and API from a registered manufacturer. The policy is not a rule and does not cover research-use-only vials. Our HHS policy explainer lists all ten conditions.
No. On 23 July 2026 FDA's Pharmacy Compounding Advisory Committee voted to recommend KPV for the 503A Bulks List, nominated for wound healing and inflammatory conditions. Law-firm summaries report the margin as 8-6 with one abstention; FDA has posted no official tally. KPV had already come off the Category 2 do-not-compound list in April 2026, alongside eleven other substances. FDA's own review scientists recommended against all seven peptides on the agenda.
Neither step makes compounding lawful. FDA must either finish notice-and-comment rulemaking or grant interim Category 1 status. As of 9 October 2026 it had done neither: our Federal Register search returned no proposed rule for the six recommended peptides.
On 7 October 2026 the Washington Post reported, citing two people familiar with the matter, that the administration is drafting a plan to allow temporary sale of some restricted peptides through compounding pharmacies. The plan has not been announced and the peptide list is unknown. We have not confirmed it, and it would not change the status of research vials sold online.
The full breakdown is in our FDA peptide vote explainer.
What about KPV in the KLOW blend?
KPV is the K in KLOW, a four-peptide blend of GHK-Cu, BPC-157, TB-500 and KPV sold pre-mixed. Our Kovera data holds eight more certificates where KPV appears inside a blend or capsule, from pairings with GHK-Cu to a four-way Cartalax mix.
A blend collapses four identity checks into one. A single purity figure on a four-component vial tells you far less than four figures on four vials, and in the wider Kovera data some blends scored above 99.8% purity while failing dose or identity checks. The detail is in our KLOW stack research read. Single-compound KPV vials are far easier to verify.
What this means
KPV has a well-characterised mechanism, mouse data since 2008 that several groups have reproduced, and research-market material that tests cleaner than most compounds we track.
It still has no human trial, no human dose and no human safety record. The July vote does not supply any of those, and FDA's own review scientists recommended against listing it. If a page sells "KPV benefits" for gut, skin or men, check whether it cites a human study. None exists yet.
Related reading
- FDA peptide vote 2026 - what the PCAC recommendation changed, and the gates still standing.
- BPC-157 and TB-500 - recommended on the same day, and KPV's blend-mates.
- GHK-Cu - the fourth KLOW component, off Category 2 in April but never voted on.
- KLOW stack research read - why pre-mixed blends are harder to verify than single vials.
- Peptide cloudy vial troubleshooting - what to check when a vial or its solvent looks wrong.
- Kovera Labs: what 1,828 published COAs show - the full corpus behind this page's purity figures.
What it's researched for
- intestinal inflammation research
- wound healing research
- skin and mucosal inflammation research
Where to source it
ALL 6 VENDORS →6 audited vendors stock KPV, but the price walk hasn't captured a current listing for it. See all 6 vendors →
Frequently asked about KPV
What is KPV peptide?
KPV is a tripeptide made of lysine, proline and valine. It is the last three residues of alpha-melanocyte-stimulating hormone (α-MSH) and keeps that hormone's anti-inflammatory activity without its pigmentation activity. In gut and immune cells it enters through the PepT1 transporter and dampens NF-κB signalling. It is not an approved drug anywhere.
What are the benefits of KPV peptide?
In mice, KPV reduced colitis severity in at least four published models between 2008 and 2017, and it lowered inflammatory signalling in human gut, airway and skin cells grown in a dish. Wound-healing and skin benefits rest on cell work and reviews. No benefit has been shown in people, because no human trial has been run.
What are the benefits of KPV for men?
None that are specific to men. Every KPV study we found used cell lines or mice, often female mice, and none looked at testosterone, sexual function or any male-specific outcome. Claims about KPV for men are marketing built on the same gut-inflammation data that applies to anyone, and that data is animal-only.
What are the side effects of KPV?
Unknown in humans. No trial has recorded adverse events. In mice, KPV given alone did not change body weight or colon inflammation markers, and KPV-loaded nanoparticles were non-toxic to gut cells. The practical risks for a research vial are the usual ones: wrong content, contamination, and endotoxin, which a certificate only rules out for the batch tested.
What KPV dose did studies use?
Mouse studies used 100 μM KPV in drinking water (Dalmasso 2008), 10 μg a day by intraperitoneal injection, or 0.1 μg intravenously three times a week (Kannengiesser 2008). Cell studies used 10 nM. These are animal protocols. No study has tested a human dose, so any human dosing chart is an extrapolation, not a published figure.
Is oral KPV or injected KPV better?
Nobody has compared them in people. In mice, oral KPV in drinking water reduced colitis, and oral nanoparticle formulations did so at much lower doses because PepT1 in the inflamed gut pulls KPV into cells. Injected KPV also worked in mice. Gut-targeted oral delivery is where most of the research effort has gone since 2010.
Is KPV FDA approved or legal?
No. KPV is not approved for any use. FDA's compounding advisory committee voted to recommend it for the 503A Bulks List on 23 July 2026, but that vote is advisory. As of 9 October 2026 FDA has published no proposed rule and no interim decision, so pharmacies still cannot lawfully compound it. Research vials sold online are unaffected by the vote.
Can you take KPV with BPC-157?
No study has tested the two together in any species. They are sold together in the four-peptide KLOW blend, but that combination has no published research behind it. KPV and BPC-157 are both unapproved and neither has controlled human safety data, so a stack doubles the unknowns rather than adding evidence.